PrE0403– Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma as Front Line Therapy
Johns Hopkins Kimmel Cancer Center in Baltimore
Sibley Memorial Hospital
The purpose of this study is to see if venetoclax in combination with obinutuzumab and bendamustine chemotherapy is effective in treating people who have follicular lymphoma and to look at the side effects associated with this combination.
This study is only open to adults with newly diagnosed follicular lymphoma (meaning they have not previously received treatment for their lymphoma). Other eligibility criteria must be met in order to join this study, please contact the study team for further details.
Participants will receive study drug over a series of 28 day cycles. For the first six cycles participants will receive venetoclax, obinutuzumab and bendamustine. During this time venetoclax will be taken orally on days 1-10 of each cycle, obinutuzumab will be administered by IV on days 1, 8, and 15 of each cycle, and bendamustine will be administered by IV on days 1 and 2 of each cycle. After the first six cycles participants whose disease is the same or improved will receive venetoclax by mouth daily and obinutuzumab by IV every 2 months for 2 years.
08/08/2020 05:02 AM